Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals (IONS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,728,877
  • Shares Outstanding, K 142,050
  • Annual Sales, $ 810,460 K
  • Annual Income, $ -28,600 K
  • 60-Month Beta 0.55
  • Price/Sales 7.29
  • Price/Cash Flow 441.45
  • Price/Book 9.93
Trade IONS with:

Options Overview Details

View History
  • Implied Volatility 44.82% ( +2.86%)
  • Historical Volatility 36.31%
  • IV Percentile 11%
  • IV Rank 18.23%
  • IV High 83.93% on 01/10/22
  • IV Low 36.10% on 11/22/22
  • Put/Call Vol Ratio 0.89
  • Today's Volume 344
  • Volume Avg (30-Day) 444
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 8,658
  • Open Int (30-Day) 7,904

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -1.06
  • Number of Estimates 7
  • High Estimate -0.32
  • Low Estimate -2.98
  • Prior Year 1.41
  • Growth Rate Est. (year over year) -175.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.21 +0.30%
on 11/28/22
45.97 -12.27%
on 11/02/22
-4.28 (-9.59%)
since 10/28/22
3-Month
40.21 +0.30%
on 11/28/22
48.82 -17.39%
on 09/12/22
-2.02 (-4.77%)
since 08/26/22
52-Week
25.04 +61.06%
on 12/02/21
48.82 -17.39%
on 09/12/22
+11.28 (+38.83%)
since 11/26/21

Most Recent Stories

More News
InMed (INM) Gets Grant to Begin Neurodegenerative Diseases Program

InMed Pharmaceuticals (INM) surges on receiving research grant funding from the Natural Sciences and Engineering Research Council of Canada (NSERC) to investigate its cannabinoid drug candidates.

ESPR : 6.59 (-3.94%)
IONS : 40.33 (-2.96%)
ASRT : 2.93 (+2.09%)
INM : 2.84 (+8.40%)
Ionis (IONS) Inks Deal to Develop Precision Genetic Medicines

Ionis (IONS) inks collaboration deal with the gene editing company, Metagenomi, to expand the former's capabilities in delivering precision genetic medicines.

AZN : 66.52 (+0.47%)
NVS : 87.90 (+0.25%)
BIIB : 294.00 (+0.72%)
IONS : 40.33 (-2.96%)
FDA Accepts Amneal's (AMRX) Parkinson's Candidate NDA For Review

Amneal Pharmaceuticals' (AMRX) shares rise after the company announces that its Parkinson's candidate IPX203 NDA has been accepted for review by the FDA.

CPRX : 16.65 (+0.97%)
ESPR : 6.59 (-3.94%)
IONS : 40.33 (-2.96%)
AMRX : 2.42 (+1.26%)
Ionis partners with Metagenomi to add gene editing to its broad technology platform

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Metagenomi today announced that the companies have entered a collaboration that will leverage...

IONS : 40.33 (-2.96%)
Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today presented positive results from a Phase 2 open-label extension (OLE) study evaluating the...

IONS : 40.33 (-2.96%)
Ionis (IONS) Q3 Earnings & Sales Beat Estimates, Stock Up

Ionis (IONS) incurs a narrower-than-expected loss in Q3. Its sales also beat estimates.

AZN : 66.52 (+0.47%)
GSK : 34.56 (+2.37%)
BIIB : 294.00 (+0.72%)
IONS : 40.33 (-2.96%)
Ionis to present at upcoming investor conferences

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor...

IONS : 40.33 (-2.96%)
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 55.41% and 7.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

IONS : 40.33 (-2.96%)
INFI : 0.5375 (-0.67%)
Ionis Pharmaceuticals: Q3 Earnings Snapshot

Ionis Pharmaceuticals: Q3 Earnings Snapshot

IONS : 40.33 (-2.96%)
Ionis reports third quarter financial results

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results for the third quarter of 2022. Financial results...

IONS : 40.33 (-2.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Ionis Pharmaceuticals discovers/develops RNA-targeted therapeutics using its proprietary antisense oligonucleotide technology. Its antisense medicines have been developed/are being developed to treat neurological, cardiovascular and specialty rare diseases.

See More

Key Turning Points

3rd Resistance Point 42.99
2nd Resistance Point 42.41
1st Resistance Point 41.37
Last Price 40.33
1st Support Level 39.75
2nd Support Level 39.17
3rd Support Level 38.13

See More

52-Week High 48.82
Last Price 40.33
Fibonacci 61.8% 39.74
Fibonacci 50% 36.93
Fibonacci 38.2% 34.12
52-Week Low 25.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar